ReviewCancer immunology, immunotherapy : CII2008
Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update.
Review in Cancer immunology, immunotherapy : CII, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer.Cancers · 2022Article
- A microwell-based impedance sensor on an insertable microneedle for real-time in vivo cytokine detection.Microsystems & nanoengineering · 2021Article
- Circulating proteolytic signatures of chemotherapy-induced cell death in humans discovered by N-terminal labeling.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Serum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay.Cancer letters · 2013Article
- Silicon micro- and nanofabrication for medicine.Advanced healthcare materials · 2013Review
- Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Article
- The potential role of thioredoxin 1 and CD30 systems as multiple pathway targets and biomarkers in tumor therapy.Cancer immunology, immunotherapy : CII · 2011Review
- Biomarkers in T cell therapy clinical trials.Journal of translational medicine · 2011Review
- Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patients.Radiology and oncology · 2011Article
- Article
- Identification and validation of SRC and phospho-SRC family proteins in circulating mononuclear cells as novel biomarkers for pancreatic cancer.Translational oncology · 2011Article
- Circulating cytokeratin 18 fragment m65-a potential marker of malignancy in colorectal cancer patients.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2009Article
- A strategy for blood biomarker amplification and localization using ultrasound.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- A novel role of serum cytochrome c as a tumor marker in patients with operable cancer.Journal of cancer research and clinical oncology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapidly detectable and easily accessible markers of tumor cell death are needed for evaluating early therapeutic efficacy for immunotherapy and chemotherapy so that patients and their physicians can decide whether to remain with a given therapeutic strategy. Currently, image-based tests such as computed tomography scans and magnetic resonance imaging are used to visualize the response of a patient's tumor, but often these evaluations are not conducted for weeks to months after treatment begins. While serum levels of secreted proteins such as carcinoembryonic antigen and prostate specific antigen are commonly monitored to gauge tumor status during therapy and between image evaluations, the levels of these proteins do not always correlate well with the actual tumor response. In laboratory studies, it has been shown that tumor cells undergoing apoptosis can release cellular components into cell culture media such as cytochrome c, nucleosomes, cleaved cytokeratin-18 and E-cadherin. Studies of patient sera have found that these and other macromolecules can be found in circulation during cancer therapy, providing a potential source of material for monitoring treatment efficacy. In the future, analysis of biofluids from severe combined immunodeficiency mice bearing patient tumor specimens treated with a targeted therapy such as Apo2L/tumor necrosis factor-related apoptosis-inducing ligand will be useful in the preclinical identification of therapy response markers. In this review, the current status of the identification of serum markers of tumor cell apoptosis is provided, as well as a discussion of critical research questions that must be addressed and the considerations necessary when identifying a marker that reflects true clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.